CTLA4 and colon carcinoma: We examined the in vivo antitumor efficacy of the anti-CTLA-4 VHH (H11)-VHHkappa conjugate in the MC38 mouse colon carcinoma and B16-F10 melanoma models (Fig. 3A and 3B).